A Tale Of Two Targeted Therapies
FDA’s oncology office director suggests Ariad’s ponatinib and ChemGenex’s Omapro represent the best and worst of times, respectively, in the quality of development programs for personalized medicines.
FDA’s oncology office director suggests Ariad’s ponatinib and ChemGenex’s Omapro represent the best and worst of times, respectively, in the quality of development programs for personalized medicines.